| 证券代码 | FPRX.O |
| 证券名称 | Five Prime Therapeutics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2013-09-18 |
| 首发价格(元) | 13 USD |
| 首发数量(股) | 4800000 |
| 首发募资额(元) | 62,400,000.00 USD |
| 首发主承销商 | Wells Fargo Securities, LLC,BMO Capital Markets Corp,Jefferies L |
| 货币单位 | USD |
| 公司名称 | Five Prime Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 111 Oyster Point Boulevard, South San Francisco, California, USA |
| 成立日期 | 2001-12 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.fiveprime.com |
| 电话 | +1 (415) 365-5600 |
| 传真 | +1 (415) 365-5601 |
| 公司简介 | Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative protein therapeutics to improve the lives of patients with serious diseases. Each of their product candidates has an innovative mechanism of action and addresses patient populations for which better therapies are needed. They have an emphasis in immuno-oncology, an area in which they have clinical, preclinical and discovery programs and product and discovery collaborations. In addition, they plan to use companion diagnostics where appropriate to allow them to select patients most likely to benefit from treatment with their product candidates. |